Journal article icon

Journal article

Adjusted particle size eliminates the need of linkage of antigen and adjuvants for appropriated T cell responses in virus-like particle-based vaccines.

Abstract:

Since the discovery of the first virus-like particle (VLP) derived from hepatitis B virus in 1980 (1), the field has expanded substantially. Besides successful use of VLPs as safe autologous virus-targeting vaccines, the powerful immunogenicity of VLPs has been also harnessed to generate immune response against heterologous and even self-antigens (2-4). Linking adjuvants to VLPs displaying heterologous antigen ensures simultaneous delivery of all vaccine components to the same antigen-present...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
NDM Experimental Medicine
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
More from this funder
Name:
Swiss Cancer League
Grant:
KFS-2993-08-2012
More from this funder
Name:
Brazilian National Counsel of Technological and Scientific Development
Grant:
Science without Borders
Publisher:
Frontiers Media
Journal:
Frontiers in Immunology More from this journal
Volume:
8
Issue:
MAR
Pages:
226
Publication date:
2017-03-01
Acceptance date:
2017-02-16
DOI:
ISSN:
1664-3224
Language:
English
Keywords:
Pubs id:
pubs:687890
UUID:
uuid:24f8ff88-07d4-4f1a-89fd-4f4965368f16
Local pid:
pubs:687890
Source identifiers:
687890
Deposit date:
2017-05-02

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP